Floatz logo

Epcoritamab

Central Nervous System Lymphoma

The Lymphoma Academic Research Organisationmonoclonal_antibodyPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the Central Nervous System Lymphoma cohort.

Asset / SponsorPhaseRating
Busulphan
Sichuan University
Phase 2/3BB
CARMUSTINE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BB
Thiotepa
Zhejiang Cancer Hospital
Phase 2B
Acalabrutinib
Jonsson Comprehensive Cancer Center
Phase 2B
Eloxatin
The Lymphoma Academic Research Organisation
Phase 2B

View all 34 →

Same molecule, other indications

Epcoritamab is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
Small Lymphocytic LymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →